You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

Drug Price Trends for GNP ANTIBACTRL-URINARY PAIN TB


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for GNP ANTIBACTRL-URINARY PAIN TB

Average Pharmacy Cost for GNP ANTIBACTRL-URINARY PAIN TB

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
GNP ANTIBACTRL-URINARY PAIN TB 46122-0622-62 0.16194 EACH 2025-01-22
GNP ANTIBACTRL-URINARY PAIN TB 46122-0622-62 0.15012 EACH 2024-12-18
GNP ANTIBACTRL-URINARY PAIN TB 46122-0622-62 0.15351 EACH 2024-11-20
GNP ANTIBACTRL-URINARY PAIN TB 46122-0622-62 0.13144 EACH 2024-10-23
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Antibacterial Drugs, Including Urinary Tract Infection Treatments

Introduction to Antibacterial Drugs Market

The global antibacterial drugs market is poised for steady growth, driven by increasing prevalence of infectious diseases and the rising challenge of antibiotic resistance. Here’s a comprehensive analysis of the market, with a focus on urinary tract infection (UTI) treatments.

Global Antibacterial Drugs Market Outlook

The global antibacterial drugs market is estimated to expand at a CAGR of 2.6% from 2021 to 2031, reaching a valuation of over $62 billion by 2031[1].

  • Market Size: The market was valued at $48 billion in 2020 and is expected to surpass $51 billion by 2025[1].
  • Growth Rate: The market is anticipated to grow at a CAGR of 2.6% during the forecast period[1].

Key Segments in the Antibacterial Drugs Market

By Drug Class

  • β-lactam: This segment is expected to witness the highest demand, with a CAGR of over 2% until 2031. β-lactam drugs are increasingly effective against both gram-positive and gram-negative bacteria[1].
  • Other Classes: Quinolone, Macrolide, Tetracycline, Aminoglycoside, Sulfonamide, and Phenicols are other significant segments[1].

By Route of Administration

  • Enteral and Parenteral: These routes are dominant, with oral therapies being particularly popular due to ease of administration[1][3].

Uncomplicated Urinary Tract Infection Market

The uncomplicated urinary tract infection (uUTI) market is a significant subset of the antibacterial drugs market.

Market Size and Growth

  • The global uUTI market is estimated to be valued at $7.2 billion in 2024 and is expected to reach $14.28 billion by 2031, growing at a CAGR of 10.23%[2].
  • Another estimate suggests the market will reach $17 billion by 2033, growing at a CAGR of 10% from 2023 to 2033[3].

Drivers of Growth

  • Increasing Prevalence: High prevalence of UTIs, especially among women and the geriatric population, drives the market[2][3].
  • Antibiotic Resistance: The rising need for novel therapies due to increasing antibiotic resistance among UTI-causing pathogens is a key driver[2][3].

Treatment and Pathogen Type

  • Antibiotics Segment: Dominates the market due to its wide acceptance and effectiveness[2].
  • Escherichia coli: This pathogen is the most common cause of UTIs and thus dominates the market[2].

Regional Analysis

North America

  • North America is expected to hold a dominant position in both the antibacterial drugs market and the uUTI market due to advanced healthcare infrastructure and high disease awareness[1][2].
  • The region faces significant challenges from antimicrobial resistant infections, with the CDC estimating 2.8 million people contracting antibiotic-resistant infections annually[1].

Asia Pacific

  • The Asia Pacific region is forecasted to exhibit significant growth in the antibacterial drugs market, driven by increasing patient populations, healthcare initiatives, and a growing geriatric population[1].
  • Japan is a key market within this region, with a large patient pool and well-established distribution networks, including e-pharmacies[1].

Price Projections and Market Trends

Antibacterial Drugs Market

  • The market is expected to grow from $51.55 billion in 2022 to $67.9 billion by 2032, at a CAGR of 5.6%[4].

Urinary Tract Infection Treatments

  • The cost of treatments for uUTIs is influenced by the increasing use of potent antibiotics and the development of novel therapies to combat antibiotic resistance. The average cost per treatment can vary widely depending on the type of antibiotic and the duration of treatment[2][3].

Challenges and Opportunities

Antibiotic Resistance

  • One of the major challenges is the increasing resistance to antibiotics, which necessitates the development of new and effective treatments. This has led to initiatives like the 10 x 20 initiative by the Infectious Diseases Society of America (IDSA) to produce new systematic antibiotics[1].

Novel Therapies

  • The development of novel therapies, such as monoclonal antibodies, presents opportunities for market growth and innovation[5].

Key Takeaways

  • The global antibacterial drugs market, including treatments for urinary tract infections, is expected to grow steadily due to increasing prevalence of infectious diseases and the need for new treatments to combat antibiotic resistance.
  • North America and the Asia Pacific region are key markets, driven by advanced healthcare infrastructure and growing patient populations.
  • The uUTI market is particularly robust, with a high CAGR driven by the need for effective treatments against antibiotic-resistant pathogens.
  • Price projections indicate significant growth, with the overall antibacterial drugs market reaching $67.9 billion by 2032.

FAQs

Q: What is the projected growth rate of the global antibacterial drugs market?

  • The global antibacterial drugs market is expected to grow at a CAGR of 2.6% from 2021 to 2031[1].

Q: Which region is expected to dominate the antibacterial drugs market?

  • North America is projected to dominate the global market during the forecast period due to its highly structured healthcare industry and increasing prevalence of infectious diseases[1].

Q: What is the estimated market size of the uncomplicated urinary tract infection market by 2031?

  • The uncomplicated urinary tract infection market is expected to reach $14.28 billion by 2031, growing at a CAGR of 10.23% from 2024 to 2031[2].

Q: Which drug class is expected to witness the highest demand in the antibacterial drugs market?

  • The β-lactam segment is expected to witness the highest demand, with a CAGR of over 2% until 2031[1].

Q: What are the major drivers of the uncomplicated urinary tract infection market?

  • The major drivers include the increasing prevalence of UTIs, especially among women and the geriatric population, and the rising need for novel therapies due to antibiotic resistance[2][3].

Sources

  1. Fact.MR: Antibacterial Drugs Market Share and Statistics - 2034
  2. Biospace: Uncomplicated Urinary Tract Infection Market Size to Hit USD 14.28 Billion by 2031
  3. Future Market Insights: Uncomplicated Urinary Tract Infection Treatment Market Size
  4. Custom Market Insights: Global Antibacterial Drugs Market Size Reach $67.9 Bn 2032
  5. Future Market Insights: Urinary Antibacterial And Antiseptic Pharmaceuticals Market

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.